FDA Approval Alert: The Need-to-Know | Denileukin Diftitox in Relapsed/Refractory Cutaneous T-Cell Lymphoma

In August 2024, the FDA denileukin diftitox-cxdl for patients with relapsed/refractory cutaneous T-cell lymphoma after 1 prior line of systemic therapy.

After a complete response letter and a subsequent biologics license application resubmission, denileukin diftitox has been approved by the FDA.
FDA Approves Denileukin Diftitox in R/R Cutaneous T-Cell Lymphoma
Article
Aug 8, 2024 12:31 PM
After a complete response letter and a subsequent biologics license application resubmission, denileukin diftitox has been approved by the FDA.